# EDGAR Filing Document

**Accession Number:** 0001746473
**File Stem:** 0001193125-23-014479
**Filing Date:** 2023-1
**Character Count:** 19046
**Document Hash:** 2cb97aa45955fb4e80b72d840d47e673
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-014479.hdr.sgml**: 20230124

**ACCESSION NUMBER**: 0001193125-23-014479

**CONFORMED SUBMISSION TYPE**: S-3MEF

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230124

**DATE AS OF CHANGE**: 20230124

**EFFECTIVENESS DATE**: 20230124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLIANT THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001746473
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 474272481
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269397
- **FILM NUMBER:** 23549522

**BUSINESS ADDRESS:**
- **STREET 1:** 260 LITTLEFIELD AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-481-6770

**MAIL ADDRESS:**
- **STREET 1:** 260 LITTLEFIELD AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**As filed with the Securities and Exchange Commission on January 24, 2023** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-3** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## PLIANT THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **47-4272481** |
| **(State or other jurisdiction of** | **(I.R.S. Employer** |
| **incorporation or organization)** | **Identification Number)** |

---

**260 Littlefield Avenue** 

**South San Francisco, California** 

**94080 (650) 481-6770** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

------

**Bernard Coulie, M.D., Ph.D.** 

**President and Chief Executive Officer** 

**Pliant Therapeutics, Inc.** 

**260 Littlefield Avenue** 

**South San Francisco, California 94080 (650) 481-6770** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

------

---

| | |
|:---|:---|
| **Sharon R. Flanagan, Esq.** | **Mike Ouimette, Esq.** |
| **Carlton Fleming, Esq.** | **General Counsel and Corporate Secretary** |
| **Sidley Austin LLP** | **Pliant Therapeutics, Inc.** |
| **555 California Street** | **260 Littlefield Avenue** |
| **Suite 2000** | **South San Francisco, California** |
| **San Francisco, California** | **94080** |
| **94104** | **(650) 481-6770** |
| **(415) 772-1200** |  |

---

------

**Approximate date of commencement of proposed sale to the public:** From time to time after this registration statement becomes effective.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☒ 333-257684

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended.** 

------

**EXPLANATORY NOTE AND INCORPORATION OF** 

**CERTAIN INFORMATION BY REFERENCE** 

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the Registrant is filing this Registration Statement on Form S-3 to register the offer and sale of an additional $17,500,020 of its securities. This Registration Statement relates to the Registrant's Registration Statement on Form S-3 (File No. 333-257684) (the "Prior Registration Statement"), initially filed on July 2, 2021, as amended and declared effective by the Securities and Exchange Commission on May 31, 2022. The required opinion and consents are filed herewith. The additional amount of securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement. Pursuant to Rule 462(b), the contents of the Prior Registration Statement, including the exhibits thereto, are incorporated by reference into this Registration Statement.

------

**PART II** 

**INFORMATION NOT REQUIRED IN PROSPECTUS** 

**Item 16. Exhibits.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Exhibits. All exhibits filed with or incorporated by reference in the Registration Statement on Form S-3 (File No. 333-257684) are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed
herewith, as part of this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Sidley Austin LLP](d453566dex51.htm) |
| 23.1\* | [Consent of Deloitte & Touche LLP](d453566dex231.htm) |
| 23.2\* | [Consent of Sidley Austin LLP (included in Exhibit 5.1)](d453566dex51.htm) |
| 24.1 | [Powers of Attorney (incorporated by reference from the signature page to the Registration statement on Form S-3, File No. 333-257684)](http://www.sec.gov/Archives/edgar/data/1746473/000119312521207743/d181175ds3asr.htm#l) |
| 107\* | [Filing Fee Table](d453566dexfilingfees.htm) |

---

------

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of South San Francisco, State of California, on January 24, 2023.

---

| | |
|:---|:---|
| **PLIANT THERAPEUTICS, INC.** | **PLIANT THERAPEUTICS, INC.** |
| /s/ Bernard Coulie | /s/ Bernard Coulie |
| By: | Bernard Coulie, M.D., Ph.D. |
| Title: President and Chief Executive Officer | Title: President and Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| Signature | Title | Date |
| /s/ Bernard Coulie | President, Chief Executive Officer and Director (Principal Executive Officer) | January 24, 2023 |
| Bernard Coulie, M.D., Ph.D. |  |  |
| /s/ Keith Cummings | Chief Financial Officer (Principal Financial and Accounting Officer) | January 24, 2023 |
| Keith Cummings, M.D., MBA |  |  |
| \* | Chairman of the Board, Director | January 24, 2023 |
| Hoyoung Huh, M.D., Ph.D. |  |  |
| \* | Director | January 24, 2023 |
| Suzanne Bruhn, Ph.D. |  |  |
| \* | Director | January 24, 2023 |
| Gayle Crowell |  |  |
| \* | Director | January 24, 2023 |
| John Curnutte, M.D. |  |  |
|  | Director | January 24, 2023 |
| Katharine Knobil, M.D. |  |  |
| \* | Director | January 24, 2023 |
| David Pyott |  |  |
| \* | Director | January 24, 2023 |
| Smital Shah, MBA |  |  |

---

---

| | |
|:---|:---|
| \*By: | /s/ Bernard Coulie  |
| Name: Bernard Coulie, M.D., Ph.D. | Name: Bernard Coulie, M.D., Ph.D. |
| Title: Attorney-in-Fact | Title: Attorney-in-Fact |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| <br> ![LOGO](g453566dsp07.jpg)  | SIDLEY AUSTIN LLP<br> 555 CALIFORNIA STREET<br> SUITE 2000<br> SAN FRANCISCO, CA 94104<br> +1 415 772 1200<br> +1 415 772 7400 FAX<br>AMERICA • ASIA PACIFIC • EUROPE |

---

January 24, 2023

Pliant Therapeutics, Inc.

260 Littlefield Avenue

South San Francisco, California 94080

Re: <u>Registration Statement on Form S-3</u> 

Ladies and Gentlemen:

We refer to the Registration Statement on Form S-3 (the "<u>Additional Registration Statement</u>") to be filed by Pliant Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), with the Securities and Exchange Commission (the "<u>Commission</u>") pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), relating to an aggregate of $17,500,020 of shares of its Common Stock, $0.0001 par value per share, that may be sold by the Company, including pursuant to the exercise of the underwriters' option to purchase additional shares under the Underwriting Agreement (as defined below)), (such shares of Common Stock are collectively referred to herein as the "<u>Shares</u>"). The Additional Registration Statement incorporates by reference the Registration Statement on Form S-3, File No. 333-257684, filed by the Company with the Commission under the Securities Act, as amended to the date hereof (as so amended, the "<u>Original Registration Statement</u>"). This opinion letter is in addition to our opinion letter that was filed as Exhibit 5.1 to the Original Registration Statement. The Shares are to be sold by the Company pursuant to an underwriting agreement dated January 24, 2023 (the "<u>Underwriting Agreement</u>") among the Company and the Underwriters named therein.

This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

We have examined the Additional Registration Statement, the Original Registration Statement, the Underwriting Agreement, the Company's amended and restated certificate of incorporation and the resolutions adopted by the board of directors of the Company and the transaction committee thereof established by such board relating to the Additional Registration Statement, the Original Registration Statement and the issuance of the shares of Common Stock, including the Shares, by the Company contemplated by the Original Registration Statement and the Additional Registration Statement. We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity

Sidley Austin (CA) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships.

------

![LOGO](g453566dsp07.jpg)

with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company.

Based on and subject to the foregoing and the other limitations, qualifications and assumptions set forth herein, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The issuance and sale of 583,334 of the Shares covered by the Additional Registration Statement pursuant to the Underwriting Agreement have been duly authorized by the Company, and such Shares will be validly issued, fully paid and non-assessable when certificates representing such Shares shall have been duly executed, countersigned and registered and duly delivered to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof or, if any such Shares are to be issued in uncertificated form, the Company's books shall reflect the issuance of such Shares to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof, in accordance with the Underwriting Agreement.

This opinion letter is limited to the General Corporation Law of the State of Delaware. We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.

We hereby consent to the filing of this opinion letter as an Exhibit to the Additional Registration Statement and to all references to our Firm included in or made a part of the Additional Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

---

| |
|:---|
| Very truly yours, |
| /s/ Sidley Austin LLP |

---

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in this Registration Statement on Form S-3 of our reports dated February 28, 2022, relating to the financial statements of Pliant Therapeutics, Inc. and the effectiveness of Pliant Therapeutics, Inc.'s internal control over financial reporting, appearing in the Annual Report on Form 10-K of Pliant Therapeutics, Inc. for the year ended December 31, 2021. We also consent to the reference to us under the heading "Experts" in the Prospectus, which is part of this Registration Statement.

/s/ Deloitte & Touche LLP

San Francisco, California

January 24, 2023

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Tables** 

**Form S-3** 

(Form Type)

**Pliant Therapeutics, Inc.** 

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security<br> Type | Security<br> Class<br> Title | Fee<br>Calculation<br>Rule | Amount<br>Registered | Proposed<br>Maximum<br>Offering<br>Price Per<br> Unit | Maximum<br>Aggregate<br>Offering<br> Price | Fee<br> Rate | Amount of<br>Registration<br>Fee(2) |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Equity | Common Stock, par value<br> $0.0001 per share | 457(o) | (1) | (1) | (1) |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Equity | Preferred Stock, par value<br> $0.0001 per share | 457(o) | (1) | (1) | (1) |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Debt | Debt Securities | 457(o) | (1) | (1) | (1) |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Other | Warrants | 457(o) | (1) | (1) | (1) |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Other | Units | 457(o) | (1) | (1) | (1) |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Unallocated (Universal) Shelf | Unallocated (Universal) Shelf | 457(o) | (1) | (1) | $17500020 | 0.00011020 | $1928.50 |
|  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  | $17500020 |  | $1928.50 |
|  | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid |  |  |  |  |
|  | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  |
|  | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $1928.50 |

---

(1) The Registrant previously registered the offer and sale of certain securities, including its common stock, par
value $0.0001 per share (the "Common Stock"), preferred stock, par value $0.0001 per share (the "Preferred Stock"), debt securities (the "Debt Securities"), warrants to purchase shares of Common Stock, shares of
Preferred Stock or Debt Securities (the "Warrants") and units representing ownership of a share of Common Stock, a share of Preferred Stock, a Debt Security and a Warrant in any combination (the "Units" and, collectively with the
Common Stock, the Preferred Stock, the Debt Securities and the Warrants, the "Securities"), having a proposed maximum aggregate offering price of $500,000,000 pursuant to its effective shelf registration statement on Form S-3 (File No. 333-257684), filed with the Securities and Exchange Commission (the "SEC") on July 2, 2021, as amended by Post-Effective Amendment No. 2
thereto, filed with the SEC on March 1, 2022, and Post-Effective Amendment No. 3 thereto, filed with the SEC on July 11, 2022 (as amended, the "Prior Registration Statement"). As of the date hereof, a balance of $270,000,000
of the Securities remains unsold under the Prior Registration Statement. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the Registrant
is hereby registering the offer and sale of an additional $17,500,020 aggregate maximum amount of the Securities. The additional amount of the Securities that is being registered for offer and sale represents no more than 20% of the maximum
aggregate offering price of the remaining Securities available to be sold under the Prior Registration Statement.

(2) Calculated in accordance with Rule 457(o) under the Securities Act. Represents the registration fee only for the
additional securities being registered.